In the third quarter of 2025, Mirador closed a $250 million Series B financing, bringing total capital raised to more than $650 million since the company launched in March 2024. The proceeds enable ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Nearly 1.5 million Americans and nearly 5% of women over the age of 55 have rheumatoid arthritis (RA), an incurable ...

Rheumatoid arthritis patients often don't notice disease flares until symptoms have already worsened substantially. As joint ...

Objective Sjögren’s is a chronic systemic autoimmune disease characterised by dryness symptoms (eyes, mouth, skin), alongside ...

Arthritis is a broad term that covers conditions in which joints become inflamed, painful, and often less mobile. Many people ...

SKYWAY (NCT07148414) is a Phase 2 basket trial of SPY072 (anti-TL1A) in patients with moderate to severely active RA, PsA, or axSpA. Enrollment is on track, and all indications are expected to readout ...

Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

Women are disproportionately affected by almost every major form of arthritis, and the gap isn’t small. The pattern shows up ...

The intricate link between endocrine disorders and cancer development has drawn significant interest, revealing how ...

Those battling chronic illness know what a long, difficult battle it is to get well again, understanding all too well that old sentiment, You don’t realize how important your health ...